Compass Therapeutics (CMPX) Stock Price, News & Analysis

Company Overview

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $1.97 to $2.08
• 50-Day Range: $1.46 to $3.38
• 52-Week Range: $0.77 to $4.08
• Volume: 179,671 shs
• Average Volume: 867,411 shs
• Market Capitalization: $282.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.38
• Consensus Rating: Buy

Compass Therapeutics Stock Analysis - MarketRank™

Compass Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 304th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Compass Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Compass Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.36) to ($0.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compass Therapeutics is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compass Therapeutics is -5.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Compass Therapeutics has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.20% of the float of Compass Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Compass Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Compass Therapeutics has recently increased by 43.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compass Therapeutics does not currently pay a dividend.

Dividend Growth

Compass Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.20% of the float of Compass Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Compass Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Compass Therapeutics has recently increased by 43.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.45

News Sentiment

Compass Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Compass Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for CMPX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Compass Therapeutics insiders have sold 18,336.92% more of their company's stock than they have bought. Specifically, they have bought $30,800.00 in company stock and sold $5,678,571.00 in company stock.

Percentage Held by Insiders

28.50% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CMPX Stock Analysis - Frequently Asked Questions

How have CMPX shares performed this year?

Compass Therapeutics' stock was trading at $1.45 on January 1st, 2025. Since then, CMPX stock has increased by 40.3% and is now trading at $2.0350.
View the best growth stocks for 2025 here.

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) posted its quarterly earnings data on Thursday, February, 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.01.

When did Compass Therapeutics IPO?

Compass Therapeutics (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel served as the underwriters for the IPO and Raymond James was co-manager.

Who are Compass Therapeutics' major shareholders?

Compass Therapeutics' top institutional shareholders include SG Americas Securities LLC (0.68%), Rhumbline Advisers (0.09%), Exchange Traded Concepts LLC (0.04%) and Simplicity Wealth LLC (0.03%). Insiders that own company stock include Orbimed Advisors Llc, Thomas J Schuetz, Vered Bisker-Leib and Jonathan Anderman.
View institutional ownership trends.

How do I buy shares of Compass Therapeutics?

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Compass Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Walmart (WMT) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 4/24/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMPX
• CIK: 1738021
• Web: www.compasstherapeutics.com
• Phone: 617-500-8099
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.38
• High Stock Price Target: $32.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +573.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-42,490,000.00
• Net Margins: N/A
• Pretax Margin: -5,618.71%
• Return on Equity: -32.37%
• Return on Assets: -30.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 31.84
• Quick Ratio: 31.84

Sales & Book Value

• Annual Sales: $850,000.00
• Price / Sales: 322.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.17 per share
• Price / Book: 1.70

Miscellaneous

• Outstanding Shares: 138,283,000
• Free Float: 98,376,000
• Market Cap: $274.49 million
• Optionable: Not Optionable
• Beta: 1.40